Home > Formulary : Adult > Recent Decisions > 2020 >
Decisions 14th July 2020
At the meeting on the 14th July the following decisions were agreed
New Drug Requests
No new Drug Requests discussed at this meeting
Approved
Shared Care Protocols/TLS changes
No new SCPs/ TLS Changes were discussed at this meeting.
Updated SCPs
- Dexamfetamine for narcolepsy and idiopathic hypersomnia
- Azathioprine for maintenance therapy in Ulcerative Colitis or Crohn's Disease
- Mercaptopurine for maintenance therapy in Ulcerative Colitis or Crohn's Disease
- Glycopyrronium Bromide for Hypersalivation
Other decisions:
Duloxetine first line for neuropathic pain in patients on methadone/buprenorphine
Recognition of the option of mirabegron and solifenacin combination therapy for treatment of OAB
The new licensed formulations of Omeprazole powder for suspension 2mg/ml and 4mg/ml was not approved for use in adults in light of several existing formulations available for patient’s needs which are more cost-effective.
Further Work Needed
- Use of Omeprazole powder for suspension 2mg/ml and 4mg/ml for use in children requires further review before a recommendation can be made